IP Library Granted Patent US 9,072,785
Granted Patent B2
US 9,072,785 · App. 14/019,850 · Granted Jul 7, 2015

Stabilized compositions of proteins having a free thiol moiety

Inventors: Gaozhong Zhu (Weston, MA); Vinh Nguyen (Chelsea, MA); Kris Lowe (Boston, MA); Zahra Shahrokh (Weston, MA)
Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.
A61K47/26A61K9/0019A61K9/19A61K31/7012A61K38/1825A61K38/47
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,072,785
App. No.
14/019,850
Granted
Jul 7, 2015
Kind
B2
Abstract

Compositions of proteins having free thiols, and methods of making and using such compositions, are described.

Claims (31)

1. A method of treating a subject having a glucocerebrosidase deficiency, the method comprising administering to the subject a composition comprising glucocerebrosidase (GCB) and a carbohydrate, wherein the carbohydrate is present in an amount sufficient to maintain the stability of the GCB, wherein the pH of the composition is less than 7.0, and wherein the carbohydrate is sucrose or trehalose.

2. The method of claim 1 , wherein the composition is produced by a method comprising providing a GCB preparation and formulating the GCB with the carbohydrate.

3. The method of claim 2 , wherein the method for producing the composition further comprises physical removal of O 2 from the composition.

4. The method of claim 2 , wherein the method for producing the composition further comprises exposing the composition to an inert gas, wherein the inert gas is present in a concentration higher than in the ambient atmosphere.

5. The method of claim 2 , wherein the method for producing the composition further comprises packaging the composition.

6. The method of claim 5 , wherein the packaging comprises contacting the GCB with an inert gas to reduce the amount of a reactive species, and introducing the GCB, the inert gas, and the carbohydrate into a gas tight container.

7. The method of claim 6 , wherein the container comprises a headspace comprising at least 90% (vol/vol) an inert gas.

8. The method of claim 7 , wherein the container is a prefilled syringe, a vial, or ampoule.

9. The method of claim 8 , wherein the prefilled syringe is a needleless syringe.

10. The method of claim 6 , wherein the inert gas is N 2 or Ar and the reactive species is O 2 .

11. The method of claim 1 , wherein the stability is at least 5-80% greater, under pre-selected conditions, than the stability of a composition which differs by lacking the carbohydrate.

12. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to increase the stability of the GCB.

13. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to inhibit the reaction of a free thiol on a first molecule of the GCB with a free thiol on a second molecule of the GCB to form an aggregate.

14. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to inhibit the formation of an aggregate formed by the reaction of a free thiol on a first molecule of the GCB with a free thiol on a second molecule of the GCB by at least 5- 80%, under pre-selected conditions, as compared to the same composition lacking the carbohydrate.

15. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient that upon storage, in a gas tight container, at a temperature of 2-8° C., for a period of 6 months, the composition will retain at least 85% of the stability the composition had prior to storage.

16. The method of claim 15 , wherein the storage occurs in darkness.

17. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to have stability comparable to that of a lyophilized composition comprising sucrose, 0.01% polysorbate-20, pH 6.0, 50 mM Citrate.

18. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to maintain biochemical integrity and bioactivity characteristics of the GCB.

19. The method of claim 1 , wherein the pH of the composition is between about 4.5 and about 6.5.

20. The method of claim 1 , wherein the composition further comprises an antioxidant, wherein the antioxidant and the carbohydrate are present in amounts sufficient to maintain the stability of the GCB.

21. The method of claim 20 , wherein the antioxidant is cysteine, cysteine-HCl, or methionine.

22. The method of claim 20 , wherein the antioxidant is present at between about 0.001 and about 10% (wt/vol).

23. The method of claim 1 , wherein the composition further comprises a surfactant.

24. The method of claim 23 , wherein the surfactant is poloxamer 188.

25. The method of claim 1 , wherein the composition contains less than about 10% O 2 .

26. The method of claim 1 , wherein the GCB has two, three, or more free thiol groups and has zero, two, four, or more thiol groups which form sulfhydryl bridges, per active unit of GCB.

27. The method of claim 1 , wherein the composition is a liquid.

28. The method of claim 1 , wherein carbohydrate is present at between about 1 and about 40% (wt/vol).

29. The method of claim 1 , wherein the composition comprises about 0.1-40 mg/ml GCB, about 0.001-10% cysteine, about 1-40% sucrose, at a pH of about 5.5-6.0, and wherein the level of dissolved O 2 is less than about 10%.

30. The method of claim 1 , wherein the composition does not comprise polysorbate.

31. The method of claim 1 , wherein the glucocerebrosidase deficiency is Gaucher disease.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2022
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 061255/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2015
From: ZHU, GAOZHONG; NGUYEN, VINH; LOWE, KRIS; SHAHROKH, ZAHRA
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035470/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2015
From: ZHU, GAOZHONG; NGUYEN, VINH; LOWE, KRIS; SHAHROKH, ZAHRA
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035470/0712 →
CHANGE OF NAME Recorded Apr 22, 2015
From: TRANSKARYOTIC THERAPIES, INC.
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035478/0250 →
Continuity (4)
Continuation 12902680 · Oct 12, 2010
Continuation 11671588 · Feb 6, 2007
Provisional Application 60771555 · Feb 7, 2006
Related Publication 20140219987A1 · Aug 7, 2014